Jim Simons’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-470,500
| Closed | -$1.88M | – | 3693 |
|
|
2025
Q2 | $1.88M | Sell |
470,500
-93,954
| -17% | -$233K | ﹤0.01% | 2147 |
|
|
2025
Q1 | $514K | Buy |
564,454
+143,055
| +34% | +$198K | ﹤0.01% | 2734 |
|
|
2024
Q4 | $1.17M | Buy |
421,399
+256,599
| +156% | +$976K | ﹤0.01% | 2409 |
|
|
2024
Q3 | $862K | Sell |
164,800
-23,039
| -12% | -$120K | ﹤0.01% | 2538 |
|
|
2024
Q2 | $838K | Buy |
187,839
+14,139
| +8% | +$68.6K | ﹤0.01% | 2421 |
|
|
2024
Q1 | $1.33M | Sell |
173,700
-44,800
| -21% | -$246K | ﹤0.01% | 2303 |
|
|
2023
Q4 | $931K | Sell |
218,500
-77,108
| -26% | -$274K | ﹤0.01% | 2449 |
|
|
2023
Q3 | $1.24M | Buy |
295,608
+56,408
| +24% | +$287K | ﹤0.01% | 2154 |
|
|
2023
Q2 | $1.33M | Buy |
239,200
+53,100
| +29% | +$314K | ﹤0.01% | 2273 |
|
|
2023
Q1 | $1.07M | Sell |
186,100
-72,800
| -28% | -$192K | ﹤0.01% | 2441 |
|
|
2022
Q4 | $272K | Buy |
258,900
+103,500
| +67% | +$181K | ﹤0.01% | 3268 |
|
|
2022
Q3 | $416K | Buy |
155,400
+37,100
| +31% | +$134K | ﹤0.01% | 3034 |
|
|
2022
Q2 | $564K | Buy |
118,300
+106,400
| +894% | +$463K | ﹤0.01% | 3091 |
|
|
2022
Q1 | $49K | Buy |
+11,900
| New | +$70K | ﹤0.01% | 3916 |
|
Jim Simons's INZY Position: Q3 2025 in Review
Jim Simons sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 470,500 shares — an estimated $1.88M sold.
Jim Simons first reported a position in INZY in Q1 2022 and held it in 14 quarters. The position peaked at $1.88M in Q2 2025. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- Jim Simons reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- Jim Simons sold 470,500 Inozyme Pharma shares in Q3 2025, an estimated $1.88M.
- Jim Simons first reported a position in Inozyme Pharma in Q1 2022 and held it in 14 quarters.
- Jim Simons's Inozyme Pharma position peaked at $1.88M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.